24/7 Market News Snapshot 08 July, 2025 – Calidi Biotherapeutics, Inc. (NYSE:CLDI)

July 8, 2025

DENVER, Colo., 08 July, 2025 (www.247marketnews.com) – (NYSE:CLDI) are discussed in this article.
Calidi Biotherapeutics, Inc. (CLDI) is experiencing significant market activity, marked by a remarkable 31.14% increase in trading value, rising from $0.247 to $0.315, alongside a trading volume of 5.11 million shares. Following its previous session close at $0.240, this upward trend signals strong investor interest and positions Calidi as a company to watch closely.

In tandem with its market performance, Calidi has been featured in a recent editorial by NetworkNewsWire (NNW), which underscores the company’s innovative contributions to cancer treatment through its precision genetic medicine platform. With nearly 20 million cancer cases diagnosed globally each year and an alarming projection by the American Cancer Society forecasting up to 35 million cases annually by 2050, the necessity for effective therapeutic strategies is more pressing than ever.

Calidi Biotherapeutics aims to tackle this growing challenge by developing therapies that safely deliver genetic medicine directly to both primary and metastatic cancer tumors. By utilizing engineered viruses capable of targeted therapy delivery, Calidi is positioned to redefine the standard of care for various cancer types, particularly through its pioneering clinical-stage immuno-oncology technology and unique stem cell-based platforms.

The company’s advanced allogeneic stem cell capabilities facilitate the transport of oncolytic viruses across multiple oncology indications, including high-grade gliomas and other solid tumors. This approach not only amplifies the therapeutic effects but also enhances patient safety, offering hope for conditions that have previously been resistant to treatment.

As Calidi Biotherapeutics continues to innovate within the oncology landscape, the insights shared through the NNW editorial highlight its dedication to addressing significant unmet medical needs while paving the way for advancements in cancer therapy.

Related news for (CLDI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.